Benefits of laboratory personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Zhang, Yong; Zhang, Pei; Zhan, Li; Du, Juanjuan; Wang, Jiangrong; Tian, Xin; Gao, Mei Hua; Hou, Yongyong

doi:10.5603/cj.a2017.0127

Cited by 4 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, high on-aspirin platelet reactivity has been described, frequently associated with HcPR. Although controversial, high on treatment platelet reactivity seems to be associated with increased CV risk (D'Ascenzo et al, 2014;Fiolaki et al, 2017;Lin et al, 2015;Wisman et al, 2014), whereas personalized antiplatelet therapy, based on genetic and PLT function tests, is increasingly emerging as a potential preventive strategy (Zhang et al, 2017). Finally, PLT products might have a role in patient risk stratification for both primary and secondary CV prevention.…”

Section: Discussionmentioning

confidence: 99%

Update on pathological platelet activation in coronary thrombosis

Elia

Montecucco

Portincasa

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Although coronary thrombosis (CT) is integral to cardiovascular outcomes, the underlying pathophysiological mechanisms remain unclear. CT may occur in case of atherosclerotic plaque erosion/rupture, or even after stenting implantation. Platelets (PLT) activation is the keystone of atherothrombosis and depends on many dysregulated elements, including endothelial dysfunction, oxidized lipoproteins, and immune response. Besides the classical view of PLT as an effector of hemostatic response, a new repertoire of PLT activities is emerging. PLT lipidome oxidation is a self‐maintaining process which promotes PLT reactivity, coagulation cascade, and inflammatory cell activation. PLT‐innate immune cell interaction is also sustained by neutrophil extracellular traps and NLRP3 inflammasome pathways. Other noteworthy emerging mechanisms are implicated in the crosstalk between PLT and surrounding cells. Especially, microvesicles (MVs) released from PLT may extend their signaling network far beyond the classical cell−cell interactions. Moreover, the recognition of noncoding RNA in PLT MVs introduce another layer of complexity in terms of intercellular signaling by a direct regulation of messenger RNA profile and gene expression in the recipient cells. The aim of this narrative review is to update the recent advance in CT and intracoronary stent thrombosis, including causal factors and potential translation of experimental evidence into the clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Update on pathological platelet activation in coronary thrombosis

Elia

Montecucco

Portincasa

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…This is in line with other studies dealing with personalized antiplatelet therapy in cardiology patients. [30][31][32] In particular, the use of platelet function testing to deescalate antiplatelet therapy and avoid bleeding complications in hyperresponders seems to be a reasonable and promising approach. 33,34 Furthermore, platelet function test might be helpful to determine the optimum timing of elective and urgent coronary artery bypass graft (CABG) surgery Editorial after P2Y12 inhibitor cessation, in order to minimize bleeding complications.…”

mentioning

confidence: 99%